Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.

ABSTRACT:

Background and purpose

We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria.

Methods

This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 years) with probable or possible VaD were randomized 2:1 to receive donepezil 5 mg/d or placebo. Coprimary outcome measures were scores on the Vascular-Alzheimer Disease Assessment Scale-Cognitive Subscale and Clinician's Interview-Based Impression of Change, plus carer interview. Analyses were performed for the intent-to-treat population with the last-observation-carried

SUBMITTER: Roman GC 

PROVIDER: S-EPMC2954887 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature